Ortho V. Mylan: Key Ruling For 2 Statutory Provisions
July 18, 2008, 12:00 AM EDT
Law360, New York (July 18, 2008, 12:00 AM EDT) -- On March 31, 2008, the Court of Appeals for the Federal Circuit (“CAFC”) issued its opinion in Ortho-McNeil Pharmaceutical Inc. v. Mylan Laboratories Inc., 520 F.3d 1358 (Fed. Cir. 2008) (“Ortho v. Mylan”), a case concerning Ortho-McNeil’s blockbuster epilepsy and migraine drug, Topamax (generic name, topiramate).
In that opinion, the CAFC affirmed the district court in all respects, holding that the basic patent for topiramate was infringed, was not invalid for obviousness or lack of enablement, and was not unenforceable for inequitable conduct. See 520 F.3d...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.